ATE403654T1 - Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren - Google Patents

Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren

Info

Publication number
ATE403654T1
ATE403654T1 AT04779219T AT04779219T ATE403654T1 AT E403654 T1 ATE403654 T1 AT E403654T1 AT 04779219 T AT04779219 T AT 04779219T AT 04779219 T AT04779219 T AT 04779219T AT E403654 T1 ATE403654 T1 AT E403654T1
Authority
AT
Austria
Prior art keywords
benzothiazole
benzimidazole
benzoxazole derivatives
lta4h modulators
lta4h
Prior art date
Application number
AT04779219T
Other languages
English (en)
Inventor
Frank Axe
Scott Bembenek
Christopher Butler
James Edwards
Anne Fourie
Cheryl Grice
Brad Savall
Kevin Tays
Jianmei Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE403654T1 publication Critical patent/ATE403654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Structural Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04779219T 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren ATE403654T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28

Publications (1)

Publication Number Publication Date
ATE403654T1 true ATE403654T1 (de) 2008-08-15

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04779219T ATE403654T1 (de) 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
AT04779375T ATE405562T1 (de) 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04779375T ATE405562T1 (de) 2003-07-28 2004-07-27 Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren

Country Status (28)

Country Link
US (2) US20050043379A1 (de)
EP (2) EP1660492B1 (de)
JP (2) JP2007500703A (de)
KR (2) KR101149379B1 (de)
CN (2) CN100591679C (de)
AR (2) AR045730A1 (de)
AT (2) ATE403654T1 (de)
AU (2) AU2004261610B2 (de)
BR (2) BRPI0413072A (de)
CA (2) CA2534212A1 (de)
CY (1) CY1108560T1 (de)
DE (2) DE602004015620D1 (de)
DK (2) DK1660491T3 (de)
ES (2) ES2313079T3 (de)
HR (2) HRP20060039A2 (de)
IL (1) IL173372A (de)
MY (1) MY145080A (de)
NO (2) NO20060771L (de)
NZ (2) NZ544970A (de)
PL (2) PL1660492T3 (de)
PT (2) PT1660492E (de)
RU (2) RU2359970C2 (de)
SG (2) SG130192A1 (de)
SI (2) SI1660492T1 (de)
TW (2) TW200520756A (de)
UA (2) UA87986C2 (de)
WO (2) WO2005012296A1 (de)
ZA (2) ZA200601716B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012296A1 (en) * 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
WO2006105304A2 (en) * 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Phenyl and pyridyl lta4h modulators
CN101193862B (zh) 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
EP1717235A3 (de) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor
CN101253171B (zh) * 2005-09-02 2011-06-15 霍夫曼-拉罗奇有限公司 苯并噁唑、噁唑并吡啶、苯并噻唑和噻唑并吡啶衍生物
BRPI0616187A2 (pt) * 2005-09-21 2011-06-14 Decode Genetics Ehf composto, composiÇço farmacÊutica, e, uso de uma quantidade terapeuticamente eficaz de um composto
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
CA2636929A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2634701C (en) 2005-12-21 2014-07-29 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
EP3205644A1 (de) 2005-12-29 2017-08-16 Celtaxsys Inc. Diaminderivate als inhibitoren der leukotrien-a4 hydrolase
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
US7989480B2 (en) * 2006-08-04 2011-08-02 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors for treating inflammation
US7728032B2 (en) * 2006-08-04 2010-06-01 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
DE602008002733D1 (de) * 2007-03-08 2010-11-04 Irm Llc Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
US20100100012A1 (en) * 2007-03-30 2010-04-22 Yoshihiro Matsumura Activity intensity measurement device
PE20091017A1 (es) * 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
NZ585085A (en) * 2007-11-16 2012-08-31 Abbott Lab Method of treating arthritis using arylsulfonamide compounds
PT2268646E (pt) * 2008-04-11 2013-12-10 Janssen Pharmaceutica Nv Aminas de tiazolopiridina-2-iloxi-fenil e de tiazolopirazina-2-iloxi-fenilo como moduladores da hidrolase de leucotrieno a4
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
MX2011012190A (es) * 2009-05-14 2011-12-08 Janssen Pharmaceutica Nv Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa.
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
ES2818977T3 (es) 2011-10-25 2021-04-14 Janssen Pharmaceutica Nv Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2968265A4 (de) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibitoren der leukotrien-a4-hydrolase
HUE035698T2 (en) * 2013-12-17 2018-05-28 Lilly Co Eli Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator
EP3233077B1 (de) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamin-d2-rezeptor-liganden
EP3233799B1 (de) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamin-d2-rezeptor-liganden
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
MX2019007411A (es) 2016-12-21 2019-08-29 Hoffmann La Roche Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
EP3801559B1 (de) 2018-05-31 2025-01-01 Celltaxis, LLC Verfahren zur minderung von lungenexazerbationen bei patienten mit atemwegserkrankungen
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CA3126021A1 (en) 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
KR20230123954A (ko) * 2020-11-19 2023-08-24 텔로 테라퓨틱스, 인코포레이티드 소분자 화합물 및 조성물
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
WO2005012296A1 (en) * 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
SI1863476T1 (sl) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.

Also Published As

Publication number Publication date
EP1660492B1 (de) 2008-08-20
PT1660492E (pt) 2008-11-13
SI1660492T1 (sl) 2009-02-28
RU2373204C2 (ru) 2009-11-20
BRPI0413072A (pt) 2006-10-03
HK1092790A1 (en) 2007-02-16
WO2005012297A9 (en) 2007-01-04
ZA200601716B (en) 2007-05-30
HRP20060041B1 (hr) 2014-06-06
KR20060054408A (ko) 2006-05-22
RU2359970C2 (ru) 2009-06-27
IL173372A (en) 2010-11-30
DE602004016002D1 (de) 2008-10-02
EP1660491A1 (de) 2006-05-31
TW200523255A (en) 2005-07-16
ES2313079T3 (es) 2009-03-01
ES2311858T3 (es) 2009-02-16
CN1860117A (zh) 2006-11-08
HK1090359A1 (en) 2006-12-22
HRP20060039A2 (en) 2006-08-31
JP2007500703A (ja) 2007-01-18
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
CN100591679C (zh) 2010-02-24
MY145080A (en) 2011-12-15
DK1660491T3 (da) 2008-11-10
TWI362383B (en) 2012-04-21
CN1856490A (zh) 2006-11-01
KR101149379B1 (ko) 2012-06-28
PL1660492T3 (pl) 2009-01-30
ATE405562T1 (de) 2008-09-15
NZ544970A (en) 2009-02-28
PL1660491T3 (pl) 2009-01-30
AU2004261610A1 (en) 2005-02-10
US20050043379A1 (en) 2005-02-24
JP2007500706A (ja) 2007-01-18
PT1660491E (pt) 2008-10-10
KR20060057593A (ko) 2006-05-26
NO20060823L (no) 2006-03-15
CA2534228A1 (en) 2005-02-10
EP1660491B1 (de) 2008-08-06
TW200520756A (en) 2005-07-01
WO2005012296A1 (en) 2005-02-10
ZA200601720B (en) 2007-11-28
JP4726238B2 (ja) 2011-07-20
US20050043378A1 (en) 2005-02-24
AR045730A1 (es) 2005-11-09
UA87986C2 (uk) 2009-09-10
BRPI0412345A (pt) 2006-10-03
AU2004261628B2 (en) 2011-05-12
SG129449A1 (en) 2007-02-26
NZ544938A (en) 2009-05-31
RU2006102510A (ru) 2006-07-27
UA82888C2 (en) 2008-05-26
AU2004261628A1 (en) 2005-02-10
HRP20060041A2 (en) 2006-11-30
CY1108560T1 (el) 2014-04-09
AU2004261610B2 (en) 2010-05-20
NO20060771L (no) 2006-04-21
RU2006102508A (ru) 2006-07-27
DK1660492T3 (da) 2008-11-03
EP1660492A1 (de) 2006-05-31
WO2005012297A1 (en) 2005-02-10
DE602004015620D1 (de) 2008-09-18
SI1660491T1 (sl) 2009-02-28
SG130192A1 (en) 2007-03-20
IL173372A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
ATE405562T1 (de) Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
ATE514682T1 (de) 4-5-diamino-n,n-dihydro-pyrazol-3-on-derivate und deren verwendung als färbemittel für keratinfasern
ATE489369T1 (de) Pyrimidinderivate und deren verwendung als cb2- modulatoren
DE60321043D1 (de) Biphenylderivate und deren verwendung als fungizide
DE60323060D1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
EP1683788A4 (de) Derivate von pyridon und deren verwendung
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
ATE442366T1 (de) Oxazolidinonderivate und ihre verwendung als antibiotika
ATE484503T1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE602004020998D1 (de) 6-(1,1-difluoralkyl)-4-aminopicolinate und deren verwendung als herbizide
ATE456568T1 (de) Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
DE602005007866D1 (de) 1-phenyl- und 1-pyridylpyrazolderivate und deren verwendung als pestizide
ATE372342T1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
DE602004028116D1 (de) Verwendung von ppar-gamma-agonisten als mittel gegen infektionen
DE60316290D1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
DE602006016104D1 (de) Neuartige oxadiazol-derivate und deren medizinische verwendung
DE602005008954D1 (de) Indazol- und indolonderivative und deren verwendung als pharmazeutika
ATE485295T1 (de) Neuartige 1,4-diazabicycloä3.2.2ünonan-derivate und deren medizinische verwendung
DE60323849D1 (de) Polybenzazolfaser und deren verwendung
IS8446A (is) Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð
ATE521632T1 (de) Metastinderivate und verwendung davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660491

Country of ref document: EP

REN Ceased due to non-payment of the annual fee